Zacks Research Has Optimistic Outlook of MD Q1 Earnings

Key Points

• Zacks Research has raised its Q1 2026 earnings per share estimate for Pediatrix Medical Group from $0.24 to $0.25, maintaining a "Strong-Buy" rating on the stock.
• The company reported a Q2 2026 earnings estimate of $0.41 EPS and achieved $0.53 EPS in its last quarterly report, exceeding analyst expectations.
• Analysts have variously rated Pediatrix Medical Group as "Moderate Buy" with an average target price of $16.75; this includes one "Strong Buy," two "Buy," and four "Hold" ratings.

Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) - Equities researchers at Zacks Research boosted their Q1 2026 earnings estimates for shares of Pediatrix Medical Group in a note issued to investors on Tuesday, August 19th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.25 for the quarter, up from their previous estimate of $0.24. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Pediatrix Medical Group's current full-year earnings is $1.38 per share. Zacks Research also issued estimates for Pediatrix Medical Group's Q2 2026 earnings at $0.41 EPS.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.11. The company had revenue of $468.84 million for the quarter, compared to the consensus estimate of $464.37 million. Pediatrix Medical Group had a net margin of 5.66% and a return on equity of 18.94%. Pediatrix Medical Group's revenue for the quarter was down 7.1% on a year-over-year basis. During the same period last year, the firm posted $0.34 EPS.

MD has been the topic of a number of other reports. Macquarie lifted their price target on Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. UBS Group boosted their target price on shares of Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $16.75.

Pediatrix Medical Group Stock Performance

MD traded up $0.0050 during trading on Friday, reaching $17.0150. The company's stock had a trading volume of 955,867 shares, compared to its average volume of 756,444. Pediatrix Medical Group has a 52-week low of $10.06 and a 52-week high of $17.67. The company's fifty day moving average price is $13.76 and its 200-day moving average price is $13.94. The company has a market capitalization of $1.48 billion, a price-to-earnings ratio of 13.19 and a beta of 1.21. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.80 and a current ratio of 1.80.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MD. Nuveen LLC acquired a new position in Pediatrix Medical Group during the first quarter worth about $8,024,000. Ameriprise Financial Inc. raised its position in shares of Pediatrix Medical Group by 175.4% in the second quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company's stock valued at $10,683,000 after buying an additional 474,186 shares during the last quarter. Oberweis Asset Management Inc. acquired a new position in shares of Pediatrix Medical Group in the fourth quarter valued at approximately $6,122,000. American Century Companies Inc. raised its position in shares of Pediatrix Medical Group by 28.6% in the second quarter. American Century Companies Inc. now owns 1,931,867 shares of the company's stock valued at $27,722,000 after buying an additional 430,029 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in Pediatrix Medical Group by 669.4% during the second quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company's stock worth $6,832,000 after purchasing an additional 414,216 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company's stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.